ABO blood group in Malagasy patients with cancer: which group predominates?

Autor: Hasiniatsy NRE; Oncologie Médicale, Faculté de Médecine d'Antananarivo, Antananarivo, 101, Madagascar., Batavisoaniatsy EE; Immunologie, Allergologie, Faculté de Médecine d'Antananarivo, Antananarivo, 101, Madagascar., Refeno V; Oncologie Médicale, Faculté de Médecine d'Antananarivo, Antananarivo, 101, Madagascar., Andriambololona M; Biologie Médicale, Faculté de Médecine d'Antananarivo, Antananarivo, 101, Madagascar., Ramahandrisoa AVN; Oncologie Médicale, Faculté de Médecine d'Antananarivo, Antananarivo, 101, Madagascar., Rafaramino F; Oncologie Médicale et Radiothérapie, Faculté de Médecine d'Antananarivo, Antananarivo, 101, Madagascar.
Jazyk: angličtina
Zdroj: The Pan African medical journal [Pan Afr Med J] 2019 Feb 12; Vol. 32, pp. 73. Date of Electronic Publication: 2019 Feb 12 (Print Publication: 2019).
DOI: 10.11604/pamj.2019.32.73.17994
Abstrakt: The blood group of Malagasy patients with cancer have never been the subject of previous publications. Our objective was to determine the blood group of Malagasy patients with cancer followed in the Medical Oncology Unit of the Soavinandriana Teaching Hospital, Antananarivo. This was a one-year retrospective study (November 2012 to October 2013) in patients over the age of 15 with histological or pathological evidence of their cancer. One hundred and thirty of the 258 patients identified had an ABO blood group determination (50.39%). Among these 130 patients, 114 patients (87.69%) had solid tumors and 16 patients (12.31%) had hematologic malignancies. Thirty seven (28.49%) patients were transfused and 93 (71.54%) not transfused. There were 57 men and 73 women (sex ratio = 0.78), the average age was 55.11 +/- 14.76 years. With regard to their blood group, 52 patients (40%) were blood group B, 44 (33.84%) group O, 27 (20.76%) group A and 7 (5.38%) group AB. The order of blood group frequency of cancer patients in our series differs from other studies. This study has allowed us to know the proportion of each blood group in our Unit and thus help us in the management of stocks of labile blood products in our hospital.
Competing Interests: The authors declare no competing interests.
Databáze: MEDLINE
Externí odkaz: